Francesco Ravera, MD, PhD, on the Rationale for Comparing cfDNA to MRI for Predicting pCR After Neoadjuvant Therapy in Breast Cancer

Video

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss a study that looked at cell-free DNA assessment compared with traditional MRI for determining pathological complete response in patients with locally advanced breast cancer.

CancerNetwork® sat down with Francesco Ravera, MD, PhD, fellow in the Department of Internal Medicine at the University of Genoa in Italy, to discuss research that was presented at the American Association for Cancer Research (AACR) Annual Meeting 2021. The research examined plasma cell-free DNA as an accurate alternative for assessing pathological complete response following neoadjuvant chemotherapy in patients with locally advanced breast cancer. To understand why the investigators looked into this comparison with traditional MRI, Ravera explained the rationale for their hypothesis.

Transcription:

Today, the standard of care for the assessment of response to neoadjuvant chemotherapy in [patients with breast cancer] is based on magnetic resonance imaging, MRI, which is the best radiological procedure for this purpose but presents data [with] suboptimal accuracy, especially in regard to the assessment of [nodal disease]. In radiological complete responders, [this requires] the assessment of nodal disease biopsy and lymph node biopsy, which is not as invasive as complete resection, but may cause collateral side effects. On the other end, cell-free DNA integrity has already shown potential for diagnostic and predictive purposes in breast cancer.

Reference

Cirmena G, Ferrando L, Ravera F, et al. Plasma cell-free DNA integrity predicts the achievement of pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract LB063.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content